Haddow J E, Knight G J, Kloza E M, Palomaki G E, Wald N J
Foundation for Blood Research, Scarborough, Maine 04070-0190.
Br J Obstet Gynaecol. 1991 Sep;98(9):859-65. doi: 10.1111/j.1471-0528.1991.tb13506.x.
To investigate the feasibility and impact of integrating a cotinine-assisted smoking intervention programme with an existing antenatal maternal serum alpha-fetoprotein (AFP) screening service for open neural tube defects.
A multisite randomized controlled trial.
139 physician offices and clinic sites in Maine providing antenatal care.
2848 pregnant women who smoked 10 or more cigarettes daily, enrolled at between 15 and 20 weeks gestation, from a population base of approximately 18,000 pregnancies.
The women were individually allocated at random to intervention or control groups within each centre at the time the serum sample was received for AFP measurement. The intervention group received an interpreted measurement of the serum cotinine, reported through the physician to the woman, along with a self-help smoking cessation booklet and a repeat serum cotinine measurement one month later, again interpreted and reported through the physician to the woman. Women in the control group received the usual anti-smoking advice provided by the antenatal care site and were not told of the study.
Birthweight, physician cooperation with study protocol (as measured by effectiveness in obtaining repeat serum samples for cotinine measurements).
Pregnancy outcome data were available for 97% of the study population, including birthweight for 2700 singleton viable pregnancies. The smoking intervention programme led to a significant 66 g increase in mean birthweight (P = 0.03; 95% CI+9 to +123 g) and to a 30% reduction in the rate of low birthweight in pregnancies managed by the 70 physicians who secured the highest rate of obtaining repeat serum samples for cotinine measurements in their intervention group. Among the remaining 69 physicians, intervention had no detectable effect on birthweight.
A cotinine-assisted smoking intervention programme managed from a central location as an adjunct to a maternal serum AFP screening service can, with the cooperation of physicians responsible for antenatal care, lead to a significant and cost-effective reduction in the number of low birthweight babies. This programme is inexpensive, requires little extra effort, and does not need specially trained personnel.
探讨将可替宁辅助戒烟干预计划与现有的产前母体血清甲胎蛋白(AFP)开放性神经管缺陷筛查服务相结合的可行性及影响。
多中心随机对照试验。
缅因州139个提供产前护理的医生办公室和诊所。
2848名每日吸烟10支或更多、妊娠15至20周、来自约18000例妊娠人群的孕妇。
在接收血清样本进行AFP检测时,将每个中心的女性随机分为干预组或对照组。干预组接受血清可替宁的解读检测结果,由医生告知孕妇,同时获得一本自助戒烟手册,并在一个月后再次进行血清可替宁检测,检测结果同样由医生解读并告知孕妇。对照组接受产前护理点提供的常规戒烟建议,且未被告知本研究。
出生体重、医生对研究方案的配合情况(以获取重复血清样本进行可替宁检测的有效性衡量)。
97%的研究人群可获得妊娠结局数据,包括2700例单胎活产妊娠的出生体重。吸烟干预计划使平均出生体重显著增加66克(P = 0.03;95%可信区间为+9至+123克),并且在干预组中,70位获取重复血清样本进行可替宁检测比例最高的医生所管理的妊娠中,低出生体重率降低了30%。在其余69位医生所管理的妊娠中,干预对出生体重未产生可检测到的影响。
在负责产前护理的医生的配合下,将中心管理的可替宁辅助戒烟干预计划作为母体血清AFP筛查服务的辅助手段,可显著且经济有效地减少低出生体重婴儿数量。该计划成本低廉,只需少量额外工作,且无需专门培训的人员。